Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
So, what is GSH and why should you care
LLY also announced in mid-February 2024 that a phase 2 trial evaluating tirzepatide for liver disease metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), met its primary endpoint where up to 74% of participants achieved resolution of MASH with no worsening of fibrosis, compared to 13% on placebo
Medical professionals should be careful and learn more before suggesting or using this treatment on patients
Heres a quick term glossary
,
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
